Incyte (INCY) Tops Q1 EPS by 4c
Get Alerts INCY Hot Sheet
EPS Growth %: +135.1%
Financial Fact:
Selling, general and administrative: 75.78M
Today's EPS Names:
FSI, RELV, NEOM, More
Join SI Premium – FREE
Incyte (NASDAQ: INCY) reported Q1 EPS of $0.67, $0.04 better than the analyst estimate of $0.63. Revenue for the quarter came in at $605 million versus the consensus estimate of $656.88 million.
2021 Financial Guidance:
The Company has reaffirmed its full year 2021 financial guidance, as detailed below. Guidance does not include revenue from any potential new product launches. However, GAAP and Non-GAAP selling, general and administrative expense guidance for 2021 includes costs to support the potential launches of ruxolitinib cream as a treatment for atopic dermatitis in the U.S., pemigatinib as a treatment for cholangiocarcinoma in the EU and Japan, and tafasitamab as a treatment for DLBCL in the EU. The 2021 financial guidance does not include the impact of any potential future strategic transactions.
|
| Current |
| Previous |
Jakafi net product revenues |
| $2,125 - $2,200 million |
| Unchanged |
Other Hematology/Oncology net product revenues |
| $145 - $160 million |
| Unchanged |
GAAP Cost of product revenues |
| 6 – 7% of net product revenues |
| Unchanged |
Non-GAAP Cost of product revenues1 |
| 5 – 6% of net product revenues |
| Unchanged |
GAAP Research and development expenses |
| $1,350 - $1,390 million |
| Unchanged |
Non-GAAP Research and development expenses2 |
| $1,220 - $1,250 million |
| Unchanged |
GAAP Selling, general and administrative expenses |
| $735 - $775 million |
| Unchanged |
Non-GAAP Selling, general and administrative expenses3 |
| $665 - $700 million |
| Unchanged |
For earnings history and earnings-related data on Incyte (INCY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Volcon (VLCN) Reports 2023 Operational and Financial Results
- H.B. Fuller (FUL) Misses Q1 EPS by 1c, Offers Guidance
- Can-Fite BioPharma (CANF) Reports FY23 Results, Issues Clinical Update
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!